Biochemia medica最新文献

{"title":"Automated urine analyzers: a comparative study of Atellica UAS 800 and UAS 60 with risk analysis.","authors":"Anita Radman, Adriana Unić, Marijana Miler, Lara Milevoj Kopčinović, Alen Vrtarić, Marija Božović, Nora Nikolac Gabaj","doi":"10.11613/BM.2025.010707","DOIUrl":"10.11613/BM.2025.010707","url":null,"abstract":"<p><strong>Introduction: </strong>This study compared analytical and technical performance of Atellica UAS 800 and UAS 60 and assessed potential patient risks if results were not reviewed by laboratory personnel.</p><p><strong>Materials and methods: </strong>The study included 463 urine samples collected from February to March 2024, analyzed on both analyzers within 2 hours by two laboratory operators. Results from the UAS 800, recorded after operator review, were considered as the reference and compared to UAS 60 results obtained before and after review. Data were evaluated using weighted kappa (kappa ≥ 0.6 considered acceptable). Technical comparison was based on operator assessment. For risk analysis 23 errors and four severity levels were defined.</p><p><strong>Results: </strong>After automatic image evaluation strong agreement was observed for calcium oxalate and yeasts (kappa: 0.83, 0.94), moderate agreement for red and white blood cells and epithelial cells (kappa: 0.75, 0.78, 0.75), weak agreement for bacteria, mucus and non-squamous epithelial cells (kappa: 0.57, 0.59, 0.40), and poorest agreement for hyaline and pathological casts and total crystals (kappa: 0.23, 0.07, 0.36). After review, kappa was acceptable for all parameters. Risk analysis identified 15 errors, with unrecognized total crystals and mucus being the most frequent (30.0%, 17.1%). Three errors were classified as intermediate risk (missing to report total crystal +1, mucus +1 and pathological casts ≥ +1), with none in high risk area. UAS 800 offers higher throughput and automatic sample aspiration, while UAS 60 uses manual aspiration.</p><p><strong>Conclusions: </strong>Atellica UAS 60 provides results comparable to UAS 800, quality of reported results remaining uncompromised even without operator review. It is suitable for low- to mid-volume laboratories and can serve as a backup in larger laboratories.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010707"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological variation of thyroid stimulating hormone, free triiodothyronine and free thyroxine in healthy subjects in Turkey.","authors":"Raziye Yıldız, Hayat Özkanay, Fatma Demet Arslan, Mehmet Köseoğlu","doi":"10.11613/BM.2025.010706","DOIUrl":"10.11613/BM.2025.010706","url":null,"abstract":"<p><strong>Introduction: </strong>Biological variation (BV) data are necessary for interpretation of test results and assessment of analytical performance. We aimed to determine the BV estimates for thyroid stimulating hormone (TSH), free triiodothyronine (fT3) and free thyroxine(fT4) in healthy subjects in Turkey and compare them with the literature findings.</p><p><strong>Materials and methods: </strong>A total of 21 Turkish healthy volunteers (12 males and 9 females) were included in the study. Blood samples were collected once a week for five weeks, and the analysis was performed using the chemiluminescent immunoassay method on an Advia Centaur XP (Siemens Diagnostic, Tarrytown, USA). Analytical variation (CV_A), within-subject BV (CV_I) and between-subject BV (CV_G) were calculated. Analytical goals, individuality index (II) and reference change value (RCV) were derived from these data. Statistical analysis was performed using BioVar: BV analysis tool v.1.0.</p><p><strong>Results: </strong>For TSH, fT3 and fT4, CV_A (confidence interval, CI) were 3.3% (2.9 to 3.8), 1.7% (1.5 to 1.9) and 2.7% (2.4 to 3.1); CV_I (CI) were 22.3% (19.3 to 26.3), 4.4% (3.8 to 5.3) and 5.1% (4.3 to 6.1); CV_G (CI) were 26.6% (19.2 to 39.8), 9.2% (6.9 to 13.6) and 8.2% (6.1 to 12.1), respectively. For TSH, fT3 and fT4, desirable total errors were 27.1%, 6.2% and 6.6%; II values were calculated as 0.84, 0.48 and 0.61; and RCV% values (decrease; increase) were - 40.3;67.6, - 10.4;11.6 and - 12.7;14.5, respectively.</p><p><strong>Conclusions: </strong>Our study provides updated BV data for thyroid function tests (TFTs) in healthy subjects in Turkey. As TFTs have shown a high degree of individuality, RCV should be preferred rather than population-based reference ranges in the assessment of serum concentrations. Our BV estimates were compatible with European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) BV meta-analysis data obtained using different immunoassay methods in different populations.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010706"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum progastrin-releasing peptide in pneumonia, chronic obstructive pulmonary disease and early-stage primary lung cancers.","authors":"Gramos Begolli, Maja Lukić, Lada Rumora, Lorna Čorak, Andrea Vukić Dugac, Marko Jakopović, Miroslav Samaržija, Ilijan Tomaš, Jelena Knežević, Željko Debeljak","doi":"10.11613/BM.2025.010702","DOIUrl":"10.11613/BM.2025.010702","url":null,"abstract":"<p><strong>Introduction: </strong>Higher concentrations of the small-cell lung cancer (SCLC) serum marker, pro-gastrin-releasing peptide (proGRP), in lung inflammations has been indicated in literature. The objective of this study was to compare serum proGRP concentration in pneumonia, chronic obstructive pulmonary disease (COPD) and early-stage primary lung cancers.</p><p><strong>Materials and methods: </strong>An observational study was performed to assess serum proGRP against other lung cancer markers in pneumonia, COPD and in stage 1/2 carcinomas. A total of 91 cases of pneumonia or chronic obstructive pulmonary disease (COPD), with 107 cases of early-stage lung adenocarcinoma (ADC), squamous cell carcinoma (SQCC) and 14 cases of neuroendocrine tumors (NET), including SCLC, were analyzed. Serum proGRP (Roche Diagnostics, Basel, Switzerland), cytokeratin 19 fragment 21-1, carcinoembryonic antigen, neuron-specific enolase and C-reactive protein were measured and compared. For the statistical analysis, Mann-Whitney U test, Kruskal-Wallis ANOVA, multiple linear and multinomial logistic regression modeling were used.</p><p><strong>Results: </strong>Compared to the early-stage ADC and SQCC, proGRP in pneumonia, COPD and in NET was higher (P ≤ 0.011 in all comparisons). In 11 cases of pneumonia and COPD, proGRP reached cut-off for SCLC of 100 ng/L. No clinically relevant differences between pneumonia or COPD and early-stage cancer were observed for other markers. Concentration of proGRP was associated with CRP (model coefficient was 0.20; P < 0.019) and both parameters contributed to classification of cases to pneumonia/COPD, ADC/SQCC, and NET categories (P < 0.004, in all cases).</p><p><strong>Conclusions: </strong>Concentrations of proGRP in pneumonia and COPD patients were higher than in patients in the ADC and SQCC early stages and could exceed the SCLC cut-off.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010702"},"PeriodicalIF":1.8,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red blood cell agglutination caused by ceftriaxone and its effect on erythrocyte parameters: a case report.","authors":"Petra Andrasic, Renata Zrinski Topic, Ivan Pavic, Jasna Lenicek Krleza","doi":"10.11613/BM.2025.011002","DOIUrl":"10.11613/BM.2025.011002","url":null,"abstract":"<p><p>Ceftriaxone, a widely used antibiotic, is one of the most common drugs to cause drug-induced immune hemolytic anemia. In this report, we describe the effect of ceftriaxone on red blood cell parameters (low red blood cell count, low hematocrit, and high erythrocyte index values) in two pediatric patients without clinical symptoms of hemolytic anemia. Although automated hematology analyzers have helped to detect incorrect results, a peripheral blood smear examination was necessary for recognizing the erythrocyte agglutinins caused by ceftriaxone. Serological testing was not possible, but the resulting drug-induced antibodies mimicked cold agglutinins in the first patient and warm agglutinins in the second patient. Timely reactions and corresponding laboratory procedures prevented potential complications due to drug administration. This report aims to present laboratory findings and preanalytical challenges in these cases and share our experiences in solving them.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"011002"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are we ready to integrate advanced artificial intelligence models in clinical laboratory?","authors":"Slavica Dodig, Ivana Čepelak, Matko Dodig","doi":"10.11613/BM.2025.010501","DOIUrl":"10.11613/BM.2025.010501","url":null,"abstract":"<p><p>The application of advanced artificial intelligence (AI) models and algorithms in clinical laboratories is a new inevitable stage of development of laboratory medicine, since in the future, diagnostic and prognostic panels specific to certain diseases will be created from a large amount of laboratory data. Thanks to machine learning (ML), it is possible to analyze a large amount of structured numerical data as well as unstructured digitized images in the field of hematology, cytology and histopathology. Numerous researches refer to the testing of ML models for the purpose of screening various diseases, detecting damage to organ systems, diagnosing malignant diseases, longitudinal monitoring of various biomarkers that would enable predicting the outcome of each patient's treatment. The main advantages of advanced AI in the clinical laboratory are: faster diagnosis using diagnostic and prognostic algorithms, individualization of treatment plans, personalized medicine, better patient treatment outcomes, easier and more precise longitudinal monitoring of biomarkers, <i>etc</i>. Disadvantages relate to the lack of standardization, questionable quality of the entered data and their interpretability, potential over-reliance on technology, new financial investments, privacy concerns, ethical and legal aspects. Further integration of advanced AI will gradually take place on the basis of the knowledge of specialists in laboratory and clinical medicine, experts in information technology and biostatistics, as well as on the basis of evidence-based laboratory medicine. Clinical laboratories will be ready for the full and successful integration of advanced AI once a balance has been established between its potential and the resolution of existing obstacles.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010501"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: Serum progastrin-releasing peptide in pneumonia, chronic obstructive pulmonary disease and early-stage primary lung cancers.","authors":"Gramos Begolli, Maja Lukić, Lada Rumora, Lorna Čorak, Andrea Vukić Dugac, Marko Jakopović, Miroslav Samaržija, Ilijan Tomaš, Jelena Knežević, Željko Debeljak","doi":"10.11613/BM.2025.011201","DOIUrl":"https://doi.org/10.11613/BM.2025.011201","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.11613/BM.2025.010702.].</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"011201"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the stability of ACTH in whole blood a genuine concern during the preanalytical phase? A systematic review.","authors":"Ahmad Dib, Damien Leleu, Stéphanie Lemaire, Laurence Duvillard, Louise Ménégaut, Damien Denimal","doi":"10.11613/BM.2025.010502","DOIUrl":"10.11613/BM.2025.010502","url":null,"abstract":"<p><p>Adrenocorticotropic hormone (ACTH) has historically been considered an unstable hormone after venous sampling, necessitating stringent conditions for the transport of blood samples to the laboratory to ensure accurate measurement. However, recent investigations suggest that ACTH may be more stable than previously assumed, raising the possibility of more flexible handling conditions. This prompted us to conduct a systematic review using the MEDLINE database to ascertain the stability of ACTH in blood samples. We included 9 studies in our final analysis from 405 reports. Our findings reveal that all studies reported a mean percentage difference (PD%) in ACTH concentrations relative to baseline below the 10% threshold when uncentrifuged tubes were stored under refrigerated conditions for 2, 4, 6, and 8 hours. In contrast, the mean PD% exceed the 10% threshold in 5 out of 7 studies investigating a storage duration of 24 hours under refrigerated conditions. Nearly all studies reported a mean PD% in ACTH concentrations relative to baseline below 10% when uncentrifuged tubes were stored at room temperature for 2, 4, and 6 hours. However, for storage durations of 8, 12, and 24 hours at room temperature, most studies observed a mean PD% exceeding 10%. In summary, our findings suggest that ACTH remains stable in uncentrifuged tubes containing EDTA for 6 h at room temperature and at least 8 h under refrigerated conditions. Our findings can assist clinical laboratories in reviewing their acceptance criteria for sample transport regarding time and temperature.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010502"},"PeriodicalIF":1.8,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling sphingolipid dynamics in late-onset preeclampsia: insights from lipidomic analysis.","authors":"Tamara Antonic, Sandra Vladimirov, Daniela Ardalic, Milica Miljkovic-Trailovic, Marija Saric-Matutinovic, Tamara Gojkovic, Jelena Munjas, Jasmina Ivanisevic, Snezana Jovicic, Jelena Vekic, Aleksandra Zeljkovic, Zeljko Mikovic, Aleksandra Stefanović","doi":"10.11613/BM.2025.010708","DOIUrl":"10.11613/BM.2025.010708","url":null,"abstract":"<p><strong>Introduction: </strong>Sphingolipids, essential to trophoblast and endothelial function, may impact inflammation in preeclampsia. However, their specific role in late-onset preeclampsia remains unclear. To address this research gap, we analyzed sphingolipid profiles in pregnancies at high risk for preeclampsia development to identify potential biomarkers and clarify their role in disease pathogenesis.</p><p><strong>Materials and methods: </strong>We monitored 90 pregnant women at high risk for preeclampsia development across four gestational points. These women were later categorized into the group of women with high risk who did not develop preeclampsia (HRG) (70 women) or the preeclampsia group (PG) (20 women). Sphingolipids (sphingosine, sphinganine, sphingosine-1-phosphate (S1P), ceramides C16:0/C24:0, and sphingomyelin C16:0) were quantified via liquid chromatography-tandem mass spectrometry.</p><p><strong>Results: </strong>Sphingolipid profiles revealed distinct patterns between groups. Concentrations of S1P in the HRG increased from the 1st trimester to delivery (P < 0.001). We did not notice significant changes in S1P during pregnancy in the PG but compared with the HRG we found significantly lower concentrations at each test point from the 2nd trimester until delivery (P = 0.020, P = 0.013, P = 0.011, respectively). Ceramides C16:0 and C24:0 demonstrated significant increases over time in HRG (P < 0.001, both). Sphingomyelin C16:0 increased significantly across pregnancy in both groups (P < 0.001 in HRG and P = 0.006 in PG), with no significant differences between groups.</p><p><strong>Conclusions: </strong>We identified S1P as a potential biomarker for late-onset preeclampsia, with lower concentrations observed in PG compared to HRG. Rising sphingomyelin concentrations in both cohorts might serve as a relevant cardiovascular risk indicator in pregnancies at high risk for preeclampsia.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010707"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic tests performance indices: an overview.","authors":"Farrokh Habibzadeh","doi":"10.11613/BM.2025.010101","DOIUrl":"10.11613/BM.2025.010101","url":null,"abstract":"<p><p>Diagnostic tests are important means in clinical practice. To assess the performance of a diagnostic test, we commonly need to compare its results to those obtained from a gold standard test. The test sensitivity is the probability of having a positive test in a diseased-patient; the specificity, a negative test result in a disease-free person. However, none of these indices are useful for clinicians who are looking for the inverse probabilities, <i>i.e.,</i> the probabilities of the presence and absence of the disease in a person with a positive and negative test result, respectively, the so-called positive and negative predictive values. Likelihood ratios are other performance indices, which are not readily comprehensible to clinicians. There is another index proposed that looks more comprehensible to practicing physicians - the number needed to misdiagnose. It is the number of people who need to be tested in order to find one misdiagnosed (a false positive or a false negative result). For tests with continuous results, it is necessary to set a cut-off point, the choice of which affects the test performance. To arrive at a correct estimation of test performance indices, it is important to use a properly designed study and to consider various aspects that could potentially compromise the validity of the study, including the choice of the gold standard and the population study, among other things. Finally, it may be possible to derive the performance indices of a test solely based on the shape of the distribution of its results in a given group of people.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010101"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucose inhibitor tubes in Croatian laboratories: are we doing well?","authors":"Alen Vrtarić, Nora Nikolac Gabaj, Ivana Ćelap","doi":"10.11613/BM.2024.030901","DOIUrl":"10.11613/BM.2024.030901","url":null,"abstract":"<p><strong>Introduction: </strong>Reliable and accurate measurement of blood glucose concentration is of crucial importance for making clinical decisions in diagnosis diabetes, gestational diabetes and impaired fasting glucose tolerance.</p><p><strong>Materials and methods: </strong>Survey was performed in form of questionnaire. Questionnaire was sent to all Croatian laboratories (N = 204) in electronic form using SurveyMonkey cloud-based software (SurveyMonkey, Inc., San Mateo, USA) as an extra-analytical module of the Croatian EQA (External Quality Assessment) provider Croatian center for external quality assessment (CROQALM) in June 2023.</p><p><strong>Results: </strong>In total 148 (73%) of laboratories responded to the survey. Large proportion of laboratories never use glucose inhibitor tubes for random glucose measurement (more than half) or for glucose function tests (one quarter). Only three laboratories use recommended glycolysis inhibitor citrate. Many other inhibitors are also used, even if some of them are not recommended for plasma glucose measurement. Glucose is almost never (93%) sampled on ice when glucose inhibitor tube is not available.</p><p><strong>Conclusions: </strong>Laboratories in Croatia do not follow the recommended procedures regarding glycolysis inhibitors for glucose determination.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"34 3","pages":"030901"},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}